What are the contraindications to using metformin in a pregnant woman with gestational diabetes?

Contraindications to Metformin Use in Gestational Diabetes

Metformin should not be used in the first trimester of pregnancy, in women with hypertension or preeclampsia, in those at risk for intrauterine growth restriction, or in women with severe renal impairment (eGFR <30 mL/min/1.73 m²). 1, 2, 3, 4

Absolute Contraindications

Based on the most recent 2024 ADA guidelines and FDA labeling, metformin is contraindicated in:

• First trimester exposure - The Endocrine Society explicitly states metformin should only be used in women "not in the first trimester" 1
• Severe renal impairment (eGFR <30 mL/min/1.73 m²) 4
• Hypersensitivity to metformin 4
• Acute or chronic metabolic acidosis, including diabetic ketoacidosis 4

Clinical Contraindications Specific to Pregnancy

The 2023-2024 ADA Standards of Care provide critical pregnancy-specific contraindications:

• Hypertension or preeclampsia - Due to potential for growth restriction or acidosis in the setting of placental insufficiency 2, 3, 2
• Risk for intrauterine growth restriction - Metformin crosses the placenta freely, achieving fetal levels equal to or higher than maternal levels, and has been associated with smaller neonates and potential growth restriction 3, 5

Relative Contraindications and Cautions

Early gestational diabetes diagnosis (<25 weeks) - The Endocrine Society suggests insulin is preferred for women diagnosed before 25 weeks gestation 1

Fasting plasma glucose ≥110 mg/dL (6.1 mmol/L) - Insulin therapy is preferred in this scenario as metformin monotherapy fails in 25-28% of GDM cases with higher baseline glucose levels 1, 2

Important Clinical Context

The evidence reveals a critical nuance: metformin is not contraindicated in gestational diabetes per se, but insulin remains the preferred first-line agent 2, 3. The most recent 2023-2024 ADA guidelines explicitly state: "Metformin and glyburide should not be used as first-line agents, as both cross the placenta to the fetus" 2, 3.

Why This Matters for Morbidity and Mortality

The concern about metformin crossing the placenta is not theoretical. Studies show:

• Umbilical cord metformin levels equal or exceed maternal levels 3, 5
• The MiG TOFU study found 9-year-old offspring exposed to metformin had higher BMI, waist-to-height ratios, and waist circumference compared to insulin-exposed children 3, 5
• Meta-analyses demonstrate metformin exposure results in smaller neonates with accelerated postnatal growth and higher childhood BMI 3, 2
• In type 2 diabetes pregnancies, metformin doubled the rate of small-for-gestational-age neonates 2

When Metformin May Be Considered

Metformin may be used as a second-line agent only when 2, 3:

• Medical nutrition therapy has failed after 1 week
• The patient refuses or cannot safely use insulin (cost, language barriers, comprehension issues)
• The patient is beyond the first trimester
• None of the above contraindications are present
• The known risks and limited long-term safety data have been discussed

Common Pitfall to Avoid

Do not continue metformin used for PCOS-related ovulation induction into pregnancy. Multiple RCTs show no benefit in preventing spontaneous abortion or GDM when metformin is continued, and there is no evidence-based need to do so 3, 5. The 2023 ADA guidelines explicitly recommend: "Metformin, when used to treat polycystic ovary syndrome and induce ovulation, should be discontinued by the end of the first trimester" 2.